Despite advances in patient screenings and breakthrough therapies that allow CF patients now to live into their mid- to late 30s or 40s, sometimes even longer, all patients are plagued by bacteria settling in their mucus, which causes inflammation in their lungs, and eventually causes their respiratory systems to fail. A major barrier to developing new and urgently needed treatments is the lack of human in vitro models that recapitulate the CF disease’s pathology.